In our study, in addition to establishing and validating a prognostic model of an 11-TF signature that was significant to predict DFS in BRCA patients through integrating TF data, gene expression dataset, and clinical information, immune infiltration analysis was also performed to investigate the correlation of immune cells and our TF signature. This evidence concerns the gene TF and invasive breast carcinoma.